xenocutuzumab-zbco (Bizengri)
Jump to navigation
Jump to search
Indications
- non-small cell lung cancer (NSCLC): with NRG1 gene fusions
- pancreatic adenocarcinoma: with NRG1 gene fusions
Dosage
- intravenous infusion every 2 weeks
- 20 mg/mL injection
Adverse effects
Mechanism of action
- bispecific antibody
- targets two proteins on the surface of cancer cells: HER2 & HER3
- blocks interaction between NRG1 & HER3, preventing the activation of a signaling pathway that promotes cancer cell growth.
More general terms
References
- ↑ Schram AM, Goto K, Kim DW et al Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 6;392(6):566-576. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39908431 PMCID: PMC11878197 Free PMC article. Clinical Trial.